The prognosis for patients with most forms of T-cell lymphoma is poor. Allogeneic hematopoietic stem-cell transplantation (HSCT) may improve the outcome.
introduction T-cell lymphomas are a heterogeneous group of diseases that account for <10% of non-Hodgkin lymphomas diagnosed in North America and Western Europe [1] . With the exception of anaplastic large cell lymphoma, T/null type (systemic) (ALCL) expressing the anaplastic lymphoma kinase protein and earlystage mycosis fungoides, the prognosis of T-cell lymphoma is generally poor compared with aggressive B-cell non-Hodgkin lymphoma. The optimal treatment of most types of T-cell lymphoma remains to be defined. Aggressive lymphoma regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) have overall response rates of 50%-70% with median progression-free survivals (PFSs) of 12-14 months [2] . Fewer than 30% of patients are long-term disease-free survivors [3] . Patients with relapsed or refractory disease are generally considered incurable with chemotherapy alone.
Stem-cell transplantation has a role in the management of T-cell lymphoma though the optimal type and timing of transplantation remain to be defined. Autologous stem-cell transplantation may improve outcome when used to consolidate first or subsequent remissions, though the majority of patients will eventually relapse [4, 5] . The utility of autologous transplantation for PTCL has not been tested in randomized trials. Several studies have suggested that allogeneic hematopoietic stem-cell transplantation (HSCT) may provide long-term disease control in T-cell lymphoma, even in patients that have failed prior autologous transplantation [6, 7] .
patients and methods patients
We examined the outcome of 52 adult patients who underwent HSCT at the Dana-Farber Cancer Institute/Brigham and Women's Hospital from 4 April 1997 to 17 February 2009. The PTCL histologies included were natural killer (NK)/T cell, enteropathy type, hepatosplenic, subcutaneous panniculitic, anaplastic T/null (systemic), peripheral T-cell NOS (PTCL NOS), angioimmunoblastic, mycosis fungoides, or T cell or NK cell other. Three patients underwent more than one allogeneic transplant. One patient underwent an ablative allogeneic transplant after recurrence after an reduced-intensity conditioning (RIC) transplant and two patients underwent a second double umbilical cord blood transplant after failing to engraft after an initial double umbilical cord blood transplant. Institutional review board approval was obtained from the Office for the Protection of Research Subjects at Dana-Farber/Harvard Cancer Center in accordance with the principles of the Declaration of Helsinki.
The conditioning regimen for ablative HSCT consisted of cyclophosphamide (3600 mg/m 2 ) and total-body irradiation (14 Gy in seven fractions). The RIC consisted of fludarabine (120 mg/m 2 ) plus i.v.
low-dose busulfan (3.2 mg/kg). The conditioning regimen for cord blood transplantation consisted predominantly of fludarabine (30 mg/m 2 for 6 days), melphalan (100 mg/m 2 for one dose on day 1), and rabbit antithymocyte globulin (ATG; 1.5 mg/kg · 4 days). Graft-versus-host disease (GVHD) prophylaxis was primarily tacrolimus based, usually in combination with methotrexate and/or sirolimus. Tacrolimus was dosed i.v. or orally starting on day-3 to achieve a target trough level of 5-10 ng/ml. For patients who received sirolimus for prophylaxis, the drug was administered orally starting day-3 to a target trough level of 3-12 ng/ml. In the absence of GVHD, immunosuppression was discontinued by 6-9 months after transplant.
Patients received bone marrow, peripheral-blood stem cells, or umbilical cord blood from matched or mismatched, related or unrelated donors. Acute graft-versus-host disease (aGVHD) was graded according to the modified consensus scale [8] . Supportive care for all patients consisted of Pneumocystis jiroveci prophylaxis and Varicella-zoster virus/herpes simplex virus prophylaxis for a minimum of 1 year. Viral load monitoring was carried out for cytomegalovirus, with preemptive treatment for reactivation.
statistics
Descriptive statistics was used to summarize patient and transplantation characteristics. Cumulative incidence curves for GVHD were constructed reflecting death or relapse as a competing risk. Cumulative incidence curves for relapse and non-relapse mortality (NRM) were constructed reflecting time to relapse and time to NRM as competing risks. The difference between cumulative incidence curves in the presence of a competing risk was tested using the Gray method [9] . Time to relapse and time to NRM were measured from the date of stem-cell infusion. Patients who were alive without relapse were censored at the time last seen alive. Overall survival (OS) and PFS were calculated using the Kaplan-Meier method. OS was defined as the time from stem-cell infusion to death from any cause. PFS was defined as the time from stem-cell infusion to relapse, disease progression, or death from any cause. The log-rank test was used for the comparisons of Kaplan-Meier curves. Prognostic factors for OS and PFS were examined in Cox proportional hazards models, whereas prognostic factors for relapse and NRM were examined in competing risks regression models [10] . Before modeling, variable clustering analysis among all covariates was carried out using VARCLUS in R (v2.10.1) to assess redundancy of covariates. To avoid overfitting the model, univariable regression analysis was first carried out and if the corresponding P value was <0.2, other than age, that variable was included in the multivariable models. Age was included in every model even though it was not a significant predictor. Proportional hazards assumption was examined in all multivariable models.
The initial dataset contained 55 transplantations from 52 distinct patients. For the three patients with multiple allogeneic HSCT, we utilized the date of the first transplantation for all data analysis except for the analysis of OS.
results

patient characteristics
Baseline patient characteristics are summarized in Table 1 . The median age was 46 years (range 24-72). The median time from diagnosis to HSCT was 11 months (range 3-186). There was a male predominance. Eleven patients had undergone a prior autologous HSCT. At the time of transplantation, 23 patients (44%) were in first or subsequent complete response (CR). Ten of these patients were in first CR while 13 were in second or are the predominantly nodal PTCL histologies, these three histologies were analyzed as a group to discern any differences in outcome compared with less common, predominantly extranodal, and generally more aggressive subtypes.
graft-versus-host disease
Incidence curves for aGVHD and chronic graft-versus-host disease (cGVHD) are shown in Figures 1 and 2 , respectively. The cumulative incidence of grade II-IV aGVHD was 21%, 10% in patients with myeloablative conditioning and 38% with RIC HSCT (P = 0.02). The cumulative incidence of grade III-IV aGVHD was 6%, 3% in myeloablative and 10% in RIC HSCT (P = 0.36). When the grade II-IV aGVHD rate was compared with and without sirolimus-containing prophylaxis, the rate was similar (21% versus 22%, respectively, P = 0.80).
The maximum cumulative incidence of cGVHD was 37%, 32% with myeloablative conditioning and 43% with RIC (P = 0.48).
The cumulative incidence of extensive cGVHD was 27%, 19% with myeloablative conditioning and 38% with RIC (P = 0.18). The cumulative incidence of cGVHD was 41% with sirolimuscontaining prophylaxis and 30% with non-sirolimuscontaining prophylaxis (P = 0.36), whereas the cumulative incidence of extensive cGVHD was 38% with sirolimuscontaining prophylaxis and 13% with non-sirolimuscontaining prophylaxis (P = 0.044).
engraftment and chimerism
Neutrophil engraftment was defined as a neutrophil count ‡0.5 · 10 9 /l while platelet engraftment was defined as a platelet count >20 000. Four patients (8%) never achieved a neutrophil count of >0.5 · 10 9 /l. Twelve patients (23%) never had a neutrophil count of <0.5 · 10 9 /l and the remaining 36 patients (69%) achieved neutrophil engraftment at a median of 13 days after HSCT (range 10-59). Twelve patients (23%) never achieved a transfusion-independent platelet count of >20 000 after transplant. Eight patients (15%) never reached a platelet original article Annals of Oncology nadir of <20 000 while the remaining 32 patients (62%) achieved platelet engraftment at a median of 17 days after HSCT (range 11-47 days). Of 21 patients undergoing RIC HSCT, day 30 and day 100 chimerism data were available for 18 and 15 patients, respectively. The median day 30 chimerism was 93% (range 2%-100%). Eleven of 18 patients (61%) achieved donor chimerism of ‡90% by day 30. Twelve of 15 assessable patients (80%) achieved donor chimerism of ‡90% by day 100. There were no identifiable predictors of low chimerism.
outcome
The median follow-up of survivors is 49 months (range 20-157). NRM at 3 years was 27%: 36% with myeloablative conditioning and 14% with RIC HSCT (P = 0.07). The cumulative incidence of relapse at 3 years was 43%: 33% with myeloablative conditioning and 57% with RIC HSCT (P = 0.049).
OS at 3 years was 41% [95% confidence interval (CI) 28% to 55%; Figure 3 ]. The cause of death for 30 patients is listed in Table 3 . The most common cause of death was disease progression. Three-year OS was 52% in the nodal histology group compared with 23% in the extranodal histology group (P = 0.17; Figure 4) . The 3-year PFS for all patients was 30% (95% CI 18% to 43%): 45% in the nodal histology group compared with 6% in the predominantly extranodal histology group (P = 0.016; figure 5 ).
In multivariable Cox regression analysis, patient-donor gender (female donor-male recipient or male donor-female recipient) mismatch was associated with decreased OS [hazard ratio (HR) 2.40, 95% CI 1.11-5.18, P = 0.026] and PFS (HR 1.99, 95% CI 1.00-3.96, P = 0.049). Year of transplant during or after 2002 (HR 0.14, P = 0.0007 for OS; HR 0.18, P = 0.002 for PFS) and nodal histology (HR 0.35, P = 0.02 for OS; HR 0.31, P = 0.003 for PFS) were associated with improved OS and PFS (Table 4) . When peripheral blood stem cells (PBSC) as the stem-cell source was included in a multivariable model, it was a significant predictor of OS and PFS (HR = 0.18, P = 0.0004 for OS; HR = 0.29, P = 0.005 for PFS). However, further investigation revealed that PBSC was confounded by year of transplant since all the PBSC transplants were carried out after 2001. When the multivariable analysis was restricted to the 44 patients transplanted during or after 2002, only nodal histology predicted for improved OS (HR 0.35, 95% CI 0.15-0.84, P = 0.018) and PFS (HR 0.30, 95% CI 0.14-0.66, P = 0.0027). Age, gender, prior autologous transplant, intensity of conditioning regimen, number of prior chemotherapies, remission status at transplant, year of transplant and type of aGVHD prophylaxis were not predictive of OS or PFS.
In multivariable competing risks regression analysis of NRM and relapse, RIC (HR 7.14, P = 0.00005) was a significant risk factor for relapse. Patients in the nodal histology group (HR 0.16, P = 0.001) and patients transplanted during or after 2002 (HR 0.11, P = 0.005) were at lower risk of relapse. Age, histology, patient-donor gender mismatch, conditioning intensity, and year of transplantation were not associated with NRM.
Nine patients received DLI after relapse from the first HSCT. The median time from transplantation to relapse for the nine patients undergoing DLI was 5.5 months. Five of nine of these patients are still alive and the median OS has not been reached in these five patients. For the nine DLI patients as a whole, the 2-and 3-year OS after transplant were 67% and 50%, respectively, whereas the 3-year PFS was 11%. The follow-up time for the five patients still alive after DLI ranges from 20 to 89 months. One patient with adult T cell leukemia/lymphoma achieved a CR with DLI, tapering of immune suppression, and antiviral therapy. A patient with cutaneous T cell lymphoma (CTCL) achieved a CR after DLI and radiation. One cutaneous lesion that was never treated with radiotherapy spontaneously regressed after DLI. Another patient with CTCL achieved a CR after DLI and low-dose alemtuzumab. A patient with ALCL and another patient with CTCL achieved PRs after DLI and tapering of immune suppression. Four patients experienced progressive disease despite DLI (one with CTCL, two with PTCL NOS, and one with extranodal NK-/T-cell lymphoma).
discussion
Our analysis indicates that allogeneic HSCT can produce long-term disease control in patients with T-cell lymphomas. Plateaus in both OS and PFS curves suggest that allogeneic HSCT could be curative in a select group of patients. The 3-year NRM of 27% and 3-year incidence of relapse of 43% are comparable with other published series in PTCL [11] . There is of course inherent selection bias in any retrospective analysis. For instance, the median age of patients in this series was 46, which is younger than a typical PTCL patient population. However, the younger demographic in this study is consistent with the population of patients historically considered for allogeneic HSCT. It is encouraging that age was not predictive of OS, PFS, or NRM suggesting that allogeneic HSCT is applicable to appropriate patients in older age ranges. The incidence of GVHD was acceptable. The incidence of grade II-IV aGVHD was 21% and the incidence of grade III-IV aGVHD was 6%. The cumulative incidence of extensive cGVHD was 27%, which is comparable with other studies of allogeneic transplantation in lymphoma [12] . Patients receiving non-sirolimus-based prophylaxis had a lower risk of cGVHD.
The risk of relapse with RIC was significantly higher than that with ablative conditioning though OS and PFS were not different. The equivalent OS with RIC and myeloablative conditioning is important for two reasons. First, most patients with PTCL are over age 60 and secondly, many patients with PTCL now undergo autologous transplantation in first remission-both demographics in which RIC is more feasible than ablative conditioning. Given the increased utilization of PBSC, it was also reassuring to find that the use of PBSC did not adversely impact OS or PFS.
In this series, HSCTs conducted after 2001 were associated with a decreased risk of relapse and improved PFS and OS. We considered as one possible explanation the fact that all the patients who received sirolimus-based GVHD prophylaxis were transplanted after 2001. In a previous publication, we reported that sirolimus decreased the risk of relapse after RIC allogeneic HSCT for B cell lymphoma was associated with a decreased risk of relapse after RIC transplantation, though this study included primarily in B-cell lymphomas [13] . Sirolimus can decrease cell proliferation and increase apoptosis in T-cell lymphoma cell lines [14] . Therefore, in theory, sirolimus could also decrease original article Annals of Oncology the risk of relapse of PTCL after allogeneic HSCT [14] . In the current analysis, however, sirolimus-based GVHD prophylaxis was not an independent predictor of improved PFS.
Another explanation for improved OS for patients transplanted after 2001 is improvement in supportive care measures and the fact that these patients were more likely to receive systemic chemotherapy after relapse and all nine patients who received DLI after relapse were transplanted after 2002. The nine patients who received DLI relapsed rapidly after transplant (median 5.5 months) yet most were alive 3 years after transplant. Five patients achieved remission after DLI and tapering immune suppression with or without additional systemic therapy or radiation. This suggests that DLI can induce a graft-versus-lymphoma effect and could have contributed in some part to improved OS.
Although this study did not have sufficient power to analyze outcome by individual histologies, we were interested in determining whether there was any difference in outcome between the three predominantly nodal histologies (PTCL NOS, AITL, and ALCL) and the other predominantly extranodal histologies. The rationale for this lies in the fact that PTCL NOS, AITL, and ALCL generally have a better prognosis with chemotherapy alone than less common histologies such as hepatosplenic T-cell lymphoma or adult T-cell leukemia/ lymphoma. The data in fact supported this hypothesis since aggregate patients with PTCL NOS, AITL, and ALCL had superior PFS, OS, and a decreased risk of relapse relative to the aggregate group of patients with other histologies, even when controlling for such factors as age and disease status at transplantation.
In summary, our study represents the largest single-institution study of allogeneic stem-cell transplantation in T-cell lymphoma published to date. Despite limitations of the study such as varied conditioning regimens, disparate stem-cell sources, and the heterogeneous histologies studied, our data suggest that allogeneic HSCT can induce long-term disease control in T-cell lymphoma, reflecting a graft-versus-lymphoma effect. GVHD and transplant related mortality incidences were acceptable and comparable with allogeneic transplantation for other diseases. The outcome for PTCL NOS, AITL, and ALCL in aggregate appeared to be better than that for other histologies. Further investigation is warranted to determine whether there is a more robust graft-versus-lymphoma effect in these histologies and if so, what the biologic reason for that effect may be.
